Allergan begins trials on hair-growth drug
Irvine, Calif. — Drugmaker Allergan is recruiting volunteers for clinical trials of a hair-growth treatment based on the active ingredient in Latisse (bimatoprost ophthalmic solution, 0.03 percent), the company’s eyelash-growth treatment.
The Orange County Register reports that the recruitment phase should be completed in February. According to information posted by Allergan on the National Institutes of Health’s ClinicalTrials.gov website, the trial’s initial phase will observe a group of 28 patients, comprising men with moderate male-pattern baldness and women with moderate female-pattern hair loss.
The Food and Drug Administration approved Latisse in 2008 for use in spurring eyelash growth. The Register reports that some doctors use Latisse off-label as a treatment for hair loss.
MORE ARTICLES IN THIS ISSUE
Recently released survey results suggest that a significant portion of young women who regularly use tanning beds were introduced to them by their mothers, the St. Petersburg (Fla.) Times reports.
The Food and Drug Administration (FDA) has approved Gardasil (human papillomavirus [HPV] quadrivalent vaccine, recombinant; Merck) for the prevention of anal cancer and associated precancerous lesions due to HPV types 6, 11, 16 and 18 in people ages 9 through 26 years, PRNewswire-USNewswire reports.
Swiss pharmaceutical company Galderma is close to acquiring Q-Med, the Sweden-based maker of Botox rival Restylane (hyaluronic acid), for about $970 million, Reuters reports.
Results of a new study suggest that patients — especially women — with psoriasis may be at increased risk for metabolic syndrome, MedPage Today reports.